
Overview
ICON plc provides clinical research outsourcing services for biotech and small to mid-sized biopharma companies. It supports programs from early-phase design through market access, and offers consulting, advisory services, and tailored clinical development. The company also focuses on areas such as genomic breakthroughs, first-in-class immunotherapies, and drug development in APAC and China.
Financials
Revenue history (in m)
Filing timeliness
No financial statement for 2024 – the filing deadline has passed. 1 of 6 financial statements was filed late (for 2021, 81 days late). All were audited by a statutory auditor.
- 2024not filed
- 202309/07/2024
- 202212/07/2023
- 202104/10/2022
- 202005/08/2021
- 201915/10/2020
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2023.
Results vs industry
Industry
Offer
- Drug formulation development
- Clinical trial drug manufacturing
- Drug stability testing
- Analytical research
- Pharmaceutical packing
- Drug labeling
- Medicine distribution
Website technology
- Website
- Drupal
- Analytics and marketing
- Google Tag Manager
Trademarks
The company currently holds no active trademarks with the Polish Patent Office. 6 marks have expired or were not registered. The first mark was filed in 2013.
| Mark | Protected until | |
|---|---|---|
| KCR | – | |
| KCR | – | |
| KCR KNOWLEDGE / COMMITMENT / RESULTS | – | |
| KCR KNOWLEDGE COMMITMENT RESULTS | – | |
| KNOWLEDGE COMMITMENT RESULTS KCR | – |
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations of will on behalf of the company independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Curandus sp. z o.o. | 13,506.21 USD | 100% |
Bank accounts
Registered as a VAT taxpayer on 2001-12-04.
27 1030 1508 0000 0008 2416 4836
68 1030 1508 0000 0008 2416 4001
07 1140 1977 0000 2292 5600 1002
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| May 7, 2024 | Commercial Companies Code notice | |
| Nov 21, 2019 | Financial statement published | |
| Aug 1, 2018 | Bankruptcy notice | |
| Nov 17, 2014 | Bankruptcy notice | |
| Nov 3, 2014 | Financial statement published |
Public aid
No public aid cases recorded in the last 10 years.
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2010-07-01 | Health-f2-2010-261358/paddington | $1.8M$1,772,643 | FP7 Cooperation |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Selvita S.A. | $91,692,114.52 | selvita.com | ||
| Iqvia Rds Poland sp. z o.o. | $67,221,056.87 | iqvia.com | ||
| PPD Poland sp. z o.o. | $59,538,223.87 | ppd.com | ||
| Eurofins Polska sp. z o.o. | $29,737,281.15 | eurofins.com | ||
| Pratia S.A. | $28,984,298.31 | pratia.com | ||
| Sieć Badawcza Łukasiewicz - Instytut Chemii Przemysłowej Imienia Profesora Ignacego Mościckiego Research institute | $20,827,884.46 | ichp.lukasiewicz.gov.pl | ||
| Narodowy Instytut Leków Research institute | $10,946,582.26 | nil.gov.pl | ||
| Sieć Badawcza Łukasiewicz - Instytut Przemysłu Organicznego Research institute | $10,664,333.00 | ipo.lukasiewicz.gov.pl | ||
| Kapadi sp. z o.o. | $7,248,714.39 | kapadi.com | ||
| Biostat sp. z o.o. | $6,243,162.72 | biostat.com.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-04-28 | Address change (Postępu 6, 02-676, Warszawa → Ul. Prosta 68, 00-838, Warszawa) | |
| 2025-04-28 | Switch to PKD 2025 (10 PKD 2007 codes → 6 PKD 2025 codes) | |
| 2024-07-18 | Share capital reduction (571,666.20 PLN → 506,246.20 PLN) | |
| 2018-05-21 | Share capital reduction (700,000.00 PLN → 571,666.20 PLN) | |
| 2015-01-12 | PKD change (Removed: 46.18.Z, 46.19.Z, 85.59.B) |
FAQ
Last updated: 2026-03-22